News about "Glenmark Pharmaceuticals"

Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma

Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.

Glenmark Pharmaceuticals | 17/12/2025 | By News Bureau

Glenmark's Aurangabad Facility Clears US FDA Inspection With Zero Observations

Glenmark Pharmaceuticals announced that the US Food and Drug Administration (US FDA) has successfully completed a pre-approval inspection of its formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad).

Glenmark Pharmaceuticals | 01/12/2025 | By Dineshwori |  121

Glenmark to Launch 8.4% Sodium Bicarbonate Injection in the US Market

Glenmark Pharmaceuticals has announced its upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial in the US market.

Glenmark Pharmaceuticals | 04/11/2025 | By Dineshwori |  101

Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001

Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.

Glenmark Pharmaceuticals | 09/09/2025 | By Dineshwori |  175

Glenmark Pharmaceuticals to Launch Micafungin for Injection in US in September 2025

Glenmark Pharmaceuticals Inc., USA has announced the September 2025 launch of Micafungin for Injection USP, 50 mg and 100 mg vials, the bioequivalent of Astellas Pharma’s Mycamine.

Glenmark Pharmaceuticals | 19/08/2025 | By Mrinmoy Dey |  156

Glenmark's IGI Signs Licensing Deal with AbbVie for Investigational Cancer Therapy

AbbVie to lead global development, manufacturing and commercialisation of Ichnos Glenmark Innovation’s (IGI) investigational cancer therapy ISB 2001 in North America, Europe, Japan, and Greater China, while Glenmark will take these roles in emerging markets.

Glenmark Pharmaceuticals | 11/07/2025 | By Dineshwori |  166

Glenmark Appoints Anurag Mantri as President

Mantri brings over 30 years of leadership experience across corporate finance, IPOs, M&A, and global compliance.

Glenmark Pharmaceuticals | 07/04/2025 | By Aishwarya |  204

Glenmark Pharmaceuticals Introduces Latanoprost Ophthalmic Solution

Glenmark’s Latanoprost Ophthalmic Solution, 0.005 percent (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan®2 Ophthalmic Solution, 0.005 percent of Upjohn US 2 LLC.

Glenmark Pharmaceuticals | 18/02/2025 | By Aishwarya |  205

Glenmark Pharmaceuticals Unveils Generic Anticoagulant Injectable Emulsion

Glenmark's Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.

Glenmark Pharmaceuticals | 24/01/2025 | By Aishwarya |  477

Glenmark Introduces Lacosamide Oral Solution

Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc.

Glenmark Pharmaceuticals | 16/12/2024 | By Aishwarya |  304